CAR-T cell therapy for recurrent glioblastoma that has a CD276 protein
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD276 found on glioblastoma cells. It's for people whose glioblastoma has come back or not responded to standard treatments, and who have no other good options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of brain tumor called glioblastoma that is confirmed by a biopsy.
- Your glioblastoma has come back or continued to grow despite standard treatments, or you cannot tolerate those treatments.
- You must be at least 18 years old and generally able to care for yourself (Karnofsky score of 60 or higher).
- A sample of your tumor must test positive for a protein called CD276. This test can be done on tissue taken within the last 2 years.
- You must have at least one measurable tumor on an MRI scan.
- Your blood counts and organ functions (like kidney, liver, and heart) must be within a safe range.
- You cannot have active infections, autoimmune diseases, or have received certain medications (like high-dose steroids) recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
This early-phase trial studies a personalized immune-cell treatment (CAR-T) for glioblastoma that has come back. It aims to shrink or control the regrowing brain tumor by using your own immune cells after processing them in a lab.
This trial tests a new type of immunotherapy called CAR-T cells, made from donor cells, for people whose glioblastoma (a type of brain cancer) has come back after standard treatment. The goal is to see if it can shrink the tumor or slow its growth.
This trial tests a new CAR-T cell treatment (SNC-109) for people with glioblastoma that has come back after initial treatment. The therapy uses your own immune cells, modified in a lab, to try to attack the tumor.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of CAR T-cell therapy that targets a specific protein (EGFRvIII) found on some glioblastoma cells. The treatment is designed to be more effective and potentially safer for people whose brain tumor has come back after previous treatments.
Hear when a new Recurrent or Progressive Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.